Recent advances in specific drug delivery systems to the kidney (reviewed in [119]), utilizing nanoparticle-platforms as a tool to deliver therapeutics directly to the damaged kidney and minimizing their systemic effect, may be an appealing strategy to use GLUT2 inhibitors as therapeutics against DKD. Here, SLC2A2 is linked to diabetic kidney disease.